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Abstract  
Mesenchymal stromal cells (MSC) support hematopoietic stem cells (HSC) in vivo and 
enhance HSC engraftment and hematopoietic recovery upon co-transplantation with HSC. 
These data have led to the hypothesis that MSC may impact the HSC niche, leading to 
changes in HSC retention and trafficking. We studied the effect of MSC administration on 
the HSC compartment in the bone marrow (BM) in mice. Following injection of MSC, HSC 
numbers in the BM were decreased coinciding with an increased cell cycle activity compared 
to PBS-injected controls. Furthermore, the frequency of macrophages was significantly 
reduced and niche factors including Cxcl12, Scf and Vcam were downregulated in endosteal 
cells. These BM changes are reminiscent to events associated with G-CSF-induced 
hematopoietic stem –and progenitor cell (HSPC) mobilization. Interestingly, co-
administration of MSC and G-CSF resulted in a two-fold increase in peripheral blood HSPC 
release compared to injection of G-CSF alone, whereas injection of MSC alone did not 
induce HSPC mobilization. After intravenous administration, MSC were only observed in the 
lungs, suggesting that MSC exert their effect on the HSC niche through a soluble mediator. 
Therefore, we tested the hypothesis that MSC-derived extracellular vesicles (EV) would be 
responsible for the observed changes in the HSC niche. Indeed, administration of EV 
resulted in downregulation of Cxcl12, Scf and Vcam and enhanced G-CSF-induced HSPC 
mobilization at similar levels as compared to MSC and G-CSF. Together, these data indicate 
that MSC induce a permissive state in the BM enhancing HSPC mobilization through the 
release of EV. 
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Introduction 
Hematopoietic stem cells (HSC) replenish the peripheral blood (PB) cell pool throughout life. 
During homeostasis, the vast majority of HSC reside in specialized niches, located in the 
perivascular area of the trabeculated region of the bone marrow (BM). This HSC 
microenvironment regulates self-renewal, cell cycle entry and differentiation of HSC and 
consists of a complex network of hematopoietic and non-hematopoietic cells. (reviewed in 
1,2).  
In the BM, the majority of HSC are found in close proximity to MSC surrounding arterioles 
and sinusoids 3-6. MSC-derived CXCL12 and Stem Cell Factor (SCF) are indispensable for HSC 
maintenance as deletion of either CXCL12 or SCF leads to hematopoietic exhaustion 7-11. HSC 
are retained in the niche by adhesion molecules, including β1-integrins, interacting with 
extracellular matrix components and with VCAM, expressed on stromal cells 12.  
The endosteal region of the BM contains a population of resident macrophages (osteal 
macrophages or osteomacs) supporting osteoblast differentiation and mineralization and 
contributing to the maintenance of HSC niches 13. Another BM-resident macrophage 
population, expressing CD169, supports the retention of HSC by acting on stromal cells in 
the niche 14. Depletion of osteomacs or CD169+ macrophages results in downregulation of 
Cxcl12, Vcam, Ang-1 and Scf and results in subsequent hematopoietic stem -and progenitor 
cell (HSPC) mobilization 13-15. 
Through administration of exogenous cytokines, HSPC can be induced to leave the niche and 
migrate towards the PB, a process called mobilization. Granulocyte-colony stimulating factor 
(G-CSF) is most commonly applied as a mobilizing agent.  
Administration of G-CSF is accompanied by neutrophil expansion and a proteolytic BM 
milieu, coinciding with decreased levels of the protease inhibitor alpha-1-antitrypsin (AAT) 
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16,17. Simultaneously with neutrophil expansion, G-CSF administration leads to depletion of 
macrophages resulting in decreased expression of Cxcl12, Vcam and Scf by BM stromal cells 
and in decreased osteoblast numbers 14,15. Together, these events result in decreased 
adhesion of HSPC to their niche and as a consequence HSPC migrate towards the PB. 
MSC are a non-hematopoietic population of cells that form CFU-F and have the capacity to 
differentiate into osteoblasts, adipocytes and chondrocytes. MSC can be isolated from the 
BM, where they are an essential part of the hematopoietic stem cell niche 2. When co-
transplanted with CD34+ umbilical cord blood-derived HSPC, MSC enhance both HSC 
engraftment and hematopoietic recovery 18,19. While the underlying mechanisms are not 
fully understood,  it was suggested that HSC homeostasis is indirectly altered through 
factors released by the injected MSC, since intravenously injected MSC could not be 
detected in the BM after administration 19.  
Given the key role of MSC in the HSC microenvironment and their effect on HSC 
engraftment and hematopoietic recovery, we have investigated the effect of MSC 
administration on the hematopoietic BM compartment. Here we show that intravenous 
administration of MSC results in changes in the BM that are reminiscent to events that 
occur during G-CSF-induced HSPC mobilization. Furthermore, co-injection of MSC and G-CSF 
synergistically enhanced HSPC mobilization, compared to G-CSF alone. MSC retained in the 
lung exerted their effects on the BM through the secretion of extracellular vesicles (EV). 
Administration of EV alone resulted in downregulation of Cxcl12, Scf and Vcam and 
enhanced G-CSF-induced HSPC mobilization at similar levels as compared to MSC. Together, 
these data indicate that MSC administration induces a permissive state in the BM through 
the release of EV, promoting HSPC mobilization. 
  
5 
 
Materials and methods 
Animals 
Eight to 12-week-old male C57BL/6-Ly5.2 and C57BL/6-Ly5.1 mice were obtained from 
Charles River Laboratories (Maastricht, The Netherlands). The animals were fed commercial 
rodent chow and acidified water ad libitum and were maintained in the animal facility of the 
LUMC under conventional conditions. All experimental protocols were approved by the 
institutional ethics committee on animal experiments. 
 
Mesenchymal stromal cells 
MSC were obtained by culturing bone chips in a 75 cm2 flask in MSC medium, containing 
αMEM (Life Technologies), 10% FCS, penicillin/streptomycin and L-Glutamine. Plastic 
adherent MSC were cultured to 95% confluency in a fully humidified atmosphere at 37°C 
and 5% CO2, harvested using trypsin and further expanded until sufficient numbers were 
obtained. MSC used throughout this study were of passage six to ten. MSC were 
administered intravenously in 0.1% Bovine Serum Albumin/Phosphate Buffered Saline (0.1% 
BSA/PBS) at a dose of 200 x103 cells per day for three consecutive days. Mice injected with 
0.1% BSA/PBS served as controls. In indicated experiments, MSC were cultured in the 
presence of recombinant murine IFN-γ (20 ng/ml) or recombinant murine TNF-α (20 ng/ml; 
both R&D Systems, Abingdon, UK) for 7 days. Where indicated, MSC were transduced with a 
lentiviral vector containing SFFV-DsRed-Firefly luciferase (SFFV-DsR-Fluc) as previously 
described 20. Images were acquired and analyzed as previously described 20. To obtain MSC 
culture supernatant, MSC at a confluency of 70-80% were cultured for 1 week in StemSpan 
(Stemcell Technologies, Köln, Germany). Subsequently, the medium was harvested, 
centrifuged to deplete for cell debris and concentrated using Centriprep YM3 filters 
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(Millipore, Amsterdam, the Netherlands) to obtain a ~20-fold concentration. In indicated 
experiments, 200 μl of MSC culture supernatant was administered intraperitoneally twice 
daily for 3 consecutive days. 
 
Cell lines 
RAW264.7 cells (gift from A. van Wengen, LUMC) were cultured in RPMI-1640 containing 
10% FCS, penicillin, streptomycin and L-glutamine. S17 and MS-5 cells (gift from F.J.T. Staal, 
LUMC) were cultured in MSC medium and MSC medium with 50 μM 2-mercaptoethanol 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) respectively. 
In co-culture experiments, 35 x103 stromal cells were cultured in their respective medium 
for 16h. Medium was removed, RAW264.7 cells were added in a 1:1 ratio and cultured for 
72 hours in MSC medium. RAW264.7 cells were either directly added to the stromal cells or 
cultured in transwells with a 0.4 µm pore size (Corning Costar). Stromal cells were harvested 
using Accumax (eBioscience). RAW264.7 cells were depleted using CD45-microbeads 
(Miltenyi, Leiden, The Netherlands) and MACS separation. 
 
Preparation of cell suspensions and BM extracellular extracts 
Twenty-two to 24 hours after the last MSC administration, mice were sacrificed by CO2 
asphyxiation. PB was obtained by intracardiac puncture and cell counts were performed on 
a Sysmex XP-300 counter (Sysmex, Etten-Leur, The Netherlands). PB was centrifuged at 
350xg and blood plasma was stored at -20 oC. Erythrocytes were lysed using a specific lysis 
buffer (LUMC Pharmacy, Leiden, The Netherlands) prior to further analysis. 
BM and spleen cells were harvested as previously described 21. 
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BM extracellular extracts were obtained by flushing femurs with 250 μl cold PBS. The cell 
suspension was centrifuged at 350xg for 7 minutes at 4 oC. The supernatant was stored at -
20 oC.  
To enumerate osteoclasts, 1 x105 BM cells were seeded in quintuplicate in a 96-well 
flatbottom plate and stained using the tartrate-resistant acid phosphatase (TRAP) staining 
kit (Sigma Aldrich) according to the manufacturer’s recommendations. 
 
Antibodies for cell analysis 
All antibodies used are described in table 1. Cells were analyzed on a Canto II FACS analyser 
with Diva software (BD Biosciences, Erebodegem, Belgium).  
 
5-FU 
5-Fluorouracil (5-FU, F6627, Sigma Aldrich) was dissolved in PBS and administered at a 
concentration of 150 mg/kg intraperitoneally. Cell recovery was determined every 2-3 days, 
but individual mice were only bled weekly to avoid excessive stress. A small volume of blood 
was drawn from the tail vein. Cell counts were performed on a Sysmex XP-300 counter. 
After lysis of erythrocytes, cells were stained with CD11b, Ly6G, BB20, CD3 and Ly6C-specific 
antibodies (table 1). 
 
Quantitative PCR 
After obtaining BM cells by flushing the femurs, the same femurs were flushed with PBS and 
RLT buffer (Qiagen) to obtain cell lysates of endosteal cells. RNA was obtained using the 
RNeasy mini kit (Qiagen) according to the manufacturer’s recommendations and cDNA was 
generated using Superscript III (Invitrogen). Primer sets used for qPCR experiments are 
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shown in table 2. Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was 
performed using TaqMan Universal Mastermix (Thermo Fischer) and Universal Probes 
(Roche) on a StepOnePlus cycler (Thermo Fischer). Relative gene expression was calculated 
using the comparative threshold cycle (CT) method, with Hprt, Abl or Gapdh as the 
endogenous reference genes.  
 
Administration of recombinant human G-CSF 
Mice were injected intraperitoneally with 10 μg recombinant human G-CSF (Amgen, 
Thousand Oaks, California, USA) in 0.2 ml 0.1 % BSA/PBS once a day, for 3 consecutive days. 
Control mice received 0.2 ml 0.1% BSA/PBS.  
 
Progenitor cell assays 
Two hundred μl of PB was depleted of erythrocytes using a specific lysis buffer (LUMC 
Pharmacy). Next, the equivalent of 100 μl of PB was cultured in duplo in 3.5-cm dishes 
containing semisolid medium supplemented with recombinant murine GM-CSF (1.25 ng/ml; 
BD-Biosciences), recombinant murine IL-3 (25 ng/ml; BD-Biosciences), recombinant human 
Erythropoietin (0.2 units/ml; LUMC Pharmacy) and recombinant human G-CSF (100 ng/ml; 
Amgen). After 6 days of culture, the number of colonies (defined as an aggregate of ≥20 
cells) was scored using an inverted light microscope. 
 
Peripheral blood cell transplantations 
Recipients were irradiated in Perspex chambers using an Orthovolt (Xstrahl Medical, Walsall, 
UK). A total dose of 9.5 Gy total body irradiation (TBI) was administered. Four hours 
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following TBI, 750 x103 PB mononuclear cells were injected via caudal vein injection in 200 
μl of 0.1% BSA/PBS. 
 
Osteoprotegerin and M-CSF 
Recombinant murine osteoprotegerin (OPG) was obtained from R&D systems (Minneapolis, 
USA), dissolved in PBS and administered intravenously prior to G-CSF administration. OPG 
concentration was determined using a mouse OPG immunoassay (R&D systems) according 
to the manufacturer’s recommendations. M-CSF concentrations were assessed using a 
mouse M-CSF ELISA (R&D Systems). 
 
Extracellular vesicles 
EV-depleted MSC medium was obtained by centrifuging MSC medium at 100,000xg at 4 °C 
for 16 hours using a Beckman Coulter Ultracentrifuge. MSC were cultured for 72 hours in 
EV-depleted medium. Culture supernatant was sequentially centrifuged at 350xg for 10 
minutes and at 10,000xg for 30 minutes to discard cell debris. Supernatant was collected 
and centrifuged for 70 minutes at 100,000xg. The pellet containing EV was washed in PBS 
for 70 minutes at 100,000xg and resuspended in PBS. EV were quantified using a qNano 
particle analyzer (Izon Science, Oxford, UK). EV preparations had a mean particle diameter 
of 133.7 ± 3.2 nm. Typically, 5.3 x1010 ± 1.7 x1010 EV were isolated per 1 x106 MSC following 
3 days of culture. Where indicated, EV were stained in Diluent C solution for 10 minutes 
using a PKH26 kit (Sigma-Aldrich). Staining was stopped by adding 1% BSA/PBS. Next, EV 
were washed for 70 minutes at 100,000xg and resuspended in PBS. 
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Statistical analysis 
All values are presented as mean with standard error of the mean (SEM). All groups were 
compared using the unpaired t-test with Welch’s correction when applicable. All statistical 
calculations were performed using GraphPad Prism software (La Jolla, California, USA). 
P≤0.05 was considered statistically significant.  
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Results 
MSC administration increases hematopoietic stem –and progenitor cell cycle activity 
To investigate the effect of MSC administration on the hematopoietic compartment in the 
BM, cohorts of C57BL/6 mice received 3 consecutive daily injections of MSC. On day 4, mice 
were sacrificed and BM cells were analyzed. The absolute number of HSC (defined as Lin-
Sca-1+c-KitHICD34-CD135-) was significantly decreased (figure 1 d), while the total number of 
white blood cells (WBC) per femur and the colony-forming capacity of the BM remained 
comparable to controls (figure 1 a, b). Moreover, there was a trend towards decreased 
numbers of LSK cells, HPC and MPP per femur (figure 1 c, e, f). To investigate whether the 
decrease in HSC numbers was due to altered cell cycle activity of HSPC, the cell cycle status 
of the hematopoietic cells after MSC administration was assessed. The frequency of LSK 
cells in the G1 phase of cell cycle was 3.2-fold increased compared to PBS-treated controls, 
while the frequencies of Lin-Sca-1+c-KitHI (LSK) cells in G0 and the S/G2/M phase were 
decreased with 64% and 50.7% of PBS controls (figure 1g). A similar shift in cell cycle activity 
was observed for HSC and HPC/MPP (supplemental figure 1 a, b). The cytoreductive agent 5-
FU kills actively cycling cells, including cycling HSPC and induces a BM stress response. In the 
PB, WBC were decreased within days after 5-FU injection (figure 1 h, i). Administration of 
MSC for 3 consecutive days followed by 5-FU injection delayed WBC recovery compared to 
controls receiving PBS and 5-FU. This delay was even more pronounced in the granulocytic 
compartment (figure 1 h, i). Together, these results indicate that administration of MSC 
leads to a reduction of the number of LSK cells in the BM and induces HSPC into cell cycle. 
 
 
MSC downregulate niche factors in the BM 
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The hematopoietic stem cell niche regulates HSC cell cycle entry. Therefore, the observed 
increase in cell cycle activity of HSPC following MSC administration, may be explained by 
changes in the niche. Macrophages have been shown to contribute to anchoring HSC in the 
niche and their depletion leads to downregulation of HSC-retention factors including CXCL12 
and VCAM in stromal cells and their depletion induced HSPC mobilization 14,15. In turn, MSC 
act on cells of the innate immune system, including macrophages 22-24. For these reasons, 
we hypothesized that MSC may alter the HSC niche through macrophages as intermediate 
cells. Therefore, the presence of osteomacs and CD169+ macrophages was assessed in BM 
following MSC administration. A significant decrease in osteomacs and CD169+ macrophages 
was observed, compared to PBS-injected controls (figure 2a-f). Moreover, osteoclasts, which 
are macrophages specialized in regulating bone metabolism, were also decreased (p=0.057, 
figure 2g). The decline in osteoclasts upon MSC administration coincided with increased 
levels of the osteoclast inhibitor osteoprotegerin (OPG) in the BM extracellular fluid 
(p=0.07), while the levels of M-CSF remained unchanged (supplemental figure 2a, c). 
It has been reported that depletion of BM macrophages in vivo results in downregulation of 
Cxcl12, Vcam, Ang-1 and Scf 13-15. Similarly, following MSC administration, the expression of 
Cxcl12 and Vcam was significantly decreased in endosteal cells, while a modest decrease in 
Scf expression was observed (figure 2h-j). 
To further study the effect of macrophages on gene expression in stromal cells, in vitro 
culture experiments were performed in which cells of the immortalized macrophage cell line 
RAW264.7 were incubated with either S17 or MS-5 stromal cells. Cultures were performed 
in a transwell-setting, to investigate the effect of secreted factors or cell-cell contact. Next, 
gene expression was assessed. Direct cell-cell contact between RAW264.7 and stromal cells 
downregulated the expression of Cxcl12, Vcam and Scf significantly, compared to S17 and 
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MS-5 cultured in the absence of RAW264.7 cells. Factors secreted by RAW264.7 cells that 
were cultured in a transwell only mildly affected the expression of Cxcl12, Vcam and Scf 
(figure 2k-m).  
Not only macrophages, but also B lymphocytes were significantly decreased in the BM and 
the peripheral blood following MSC administration (supplemental figure  2d-f). This 
decrease coincided with a significant reduction in Il-7 expression in endosteal cells. Given 
the crucial role of IL-7 in B lymphopoiesis25, these results suggest that MSC administration 
may impair B lymphopoiesis in the bone marrow.  
 
  
MSC enhance G-CSF-induced HSPC mobilization  
The depletion of macrophages and downregulation of Cxcl12, Vcam and Scf observed 
following MSC administration have been reported to also occur during G-CSF-induced HSPC 
mobilization 15,26. Therefore, we hypothesized that MSC administration may affect G-CSF-
induced HSPC mobilization. To this end, MSC were administered for 3 days to mice that 
were simultaneously mobilized with G-CSF. MSC and G-CSF co-injection induced a 2-fold 
increase in HSPC mobilization compared to G-CSF administration alone, while administration 
of MSC alone did not induce HSPC migration (figure 3a). This effect was specific for MSC 
since co-injection of splenocytes and G-CSF did not enhance HSPC mobilization 
(supplemental figure 3a). A modest increase in LSK cells was observed in the PB (figure 3b). 
To investigate whether MSC and G-CSF co-administration increased the number of long-
term repopulating HSC in the PB, equal numbers of PB cells, obtained after co-injection of 
MSC and G-CSF or after G-CSF administration alone, were transplanted into lethally 
irradiated recipient mice. Recipients of PB obtained from MSC and G-CSF mobilized donors 
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showed significantly higher levels of donor leukocytes and granulocytes up to 19 weeks 
post-transplantation, compared to recipients of G-CSF-mobilized PB (figure 3c, d). This 
indicates that co-administration of MSC and G-CSF enhanced the mobilization of HSC with 
long-term repopulating ability compared to G-CSF alone. 
Previously, it has been shown that the immunomodulatory capacity of MSC is enhanced in 
an inflammatory environment 24. To examine whether exposure to inflammatory cytokines 
further enhances the capacity of MSC to increase G-CSF-induced HSPC mobilization, MSC 
were stimulated with IFN-γ and TNF-α prior to co-administration with G-CSF. IFN-γ and TNF-
α-stimulated MSC indeed enhanced G-CSF mobilization, but cytokine-stimulated MSC did 
not further enhance this effect compared to unstimulated MSC (figure 3e).  
The effect that MSC exert on the HSC niche seems to be independent of the effect 
established by G-CSF, since administration of MSC at 3 days prior to G-CSF administration 
induced the same enhancement of G-CSF-induced mobilization as simultaneous MSC and G-
CSF administration (figure 3f). In addition, administration of MSC does not increase the 
levels of neutrophil elastase in the bone marrow (supplemental figure 3b; p= 0.28). A direct 
effect of G-CSF on MSC can be excluded, as MSC do not express the G-CSF receptor 
(supplemental figure 3c). Since osteoclasts were decreased upon MSC administration in 
combination with an increase in OPG (figure 2g and supplemental figure 2a), we assessed 
whether administration of OPG would enhance G-CSF-induced HSPC mobilization. However, 
no effect of OPG on G-CSF-induced mobilization was observed (supplemental figure 2b). To 
investigate the effect of MSC and G-CSF co-administration on niche genes, the expression of 
Cxcl12, Vcam and Scf was assessed in endosteal cells. As expected, the expression of these 
genes was decreased following G-CSF administration. Moreover, co-administration of MSC 
and G-CSF even further downregulated the expression of these genes (figure 3 g-i).  
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MSC enhance G-CSF-induced mobilization through a soluble factor 
To investigate the fate of MSC upon intravenous administration, MSC transduced with a 
lentiviral construct containing SFFV-DsR-Fluc were administered for 3 days and visualized by 
luciferin. Upon intravenous administration, MSC migrated towards the lungs. No MSC 
migration to other locations was observed. This may be due to the sensitivity of the 
technique as a minimum of 5,000 MSC is required to obtain a signal that is distinguishable 
from background 20. However, these results are in line with previous observations 19. 
Since no MSC migration towards the BM was observed, we hypothesized that upon 
entrapment in the lungs, MSC secrete soluble factors that in turn affect the HSC niche and 
enhance G-CSF-induced HSPC mobilization. Therefore, MSC culture supernatant was 
administered to recipients that were simultaneously mobilized with G-CSF. Co-
administration of MSC culture supernatant and G-CSF significantly enhanced G-CSF-induced 
mobilization, while administration of culture supernatant alone did not affect HSPC 
migration towards the PB (figure 3k).  
 
MSC-derived extracellular vesicles enhance G-CSF induced HSPC mobilization 
MSC have been reported to secrete extracellular vesicles (EV) 27. To investigate whether EV 
are the supernatant-derived factor that enhanced G-CSF-induced HSPC mobilization, EV that 
were derived from 2 x106-0.2 x106 MSC were administered intravenously for 3 days to 
recipients that were simultaneously mobilized with G-CSF. Co-administration of EV and G-
CSF induced HSPC mobilization at similar levels as co-injection of MSC and G-CSF (figure 4a). 
Moreover, administration of MSC-derived EV enhanced cell cycle activity of LSK cells and 
downregulated expression of Cxcl12, Vcam and Scf similar to MSC administration (figure 4 b-
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e). Previously, it has been shown that MSC-derived EV migrate to the BM 28. To investigate 
which BM cells were able to engulf MSC-derived EV, BM cells were incubated with PKH26-
labeled EV for 4 hours and the PKH26+ cells were identified. About 28% of the CD45+ BM 
cells were able to engulf MSC-derived EV (figure 4f). Since >59% of the monocytic cells 
engulfed EV (figure 4f), we further investigated the phenotype of the EVPOS monocytic cells. 
EVPOS monocytic cells expressed F4/80, CD68 and MERTK at higher levels than EVNEG 
monocytic cells. In addition, about 50% of the EVPOS cells expressed the M-CSF receptor 
(CD115; figure 4G-J). This indicates that macrophages are the main EV-engulfing population 
in the BM. 
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Discussion 
MSC are a cellular component of the HSC niche and play a major role in the maintenance of 
HSC in the BM 1,2. In addition, in an experimental transplantation model, co-administration 
of MSC and HSPC has a beneficial effect on HSC engraftment and hematopoietic recovery 
18,19. This suggests that MSC are capable of influencing the HSC niche, leading to changes 
that result in altered HSC homeostasis.  
Here, we show that MSC administration indeed affects the HSC niche, as well as the BM 
hematopoietic compartment. Upon MSC administration, HSC numbers in the BM were 
decreased, coinciding with increased HSC cell cycling activity. Furthermore, MSC 
administration induced a decrease in BM macrophage subsets and concomitant 
downregulation of Cxcl12, Vcam and Scf expression in endosteal cells. Previous studies have 
shown that BM macrophages have a regulatory role in hematopoiesis and in the HSC niche 
29. Furthermore, depletion of osteal macrophages and a downregulation of Cxcl12, Scf and 
Ang-1 mRNA is also observed during G-CSF-induced HSPC mobilization15.  In steady state, 
macrophages regulate granulopoiesis and induce HSPC egress from the BM through 
circadian regulation of Cxcl12 in stromal cells 30. The decrease in Cxcl12 expression and HSPC 
egress is preceded by the downregulation of Liver X receptor(LXR)-target gene 
downregulation in macrophages30. Depletion of BM macrophages results in downregulation 
of Cxcl12, Vcam and Scf, increased HSC proliferation and HSPC mobilization 13-15,31. Together, 
these and our data suggest that HSC-retaining factors in stromal cells are decreased due to 
macrophage depletion upon MSC administration and that increased HSPC cycling and 
mobilization may be a direct result of these events. This effect was specific for MSC since co-
injection of splenocytes and G-CSF did not enhance HSPC mobilization. 
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To study the interaction between macrophages and stromal cells, we performed in vitro 
experiments in which RAW264.7 macrophages were co-cultured with stromal cells. Cell-cell 
contact between RAW264.7 and stromal cells downregulated Cxcl12, Vcam and Scf 
expression in stromal cells, while soluble factors secreted by RAW264.7 macrophages hardly 
influenced the expression of HSC-supporting genes. This further strenghtens the regulatory 
role of macrophages in the stem cell niche and indicates that cell-cell contact between 
stromal cells and macrophages is required for the downregulation of these factors. 
When MSC were co-administered with G-CSF, HSPC mobilization was significantly enhanced, 
indicating that the HSC niche is alterered as a result of MSC injection. As these MSC are 
trapped in the lungs upon administration, it is conceivable that the observed increased 
mobilization is induced by a secreted factor.  We considered that EV secreted by MSC could 
play such a role and therefore we embarked on experiments where we co-administered 
MSC or MSC-derived EV and G-CSF. Indeed, co-injection of EV and G-CSF induced HSPC 
mobilization at similar levels as MSC and G-CSF.  Co-administration of MSC or MSC-derived 
EV and G-CSF further downregulated the expression of Cxcl12, Vcam and Scf in endosteal 
cells, compared to injection of either G-CSF or MSC alone. Moreover, the events induced by 
MSC administration are independent of the events induced by G-CSF, since sequential 
administration of MSC and G-CSF also enhanced HSPC mobilization.  
We show that, in vitro, MSC-derived EV are engulfed by F4/80+MERTK+CD68+ BM-derived 
macrophages. Previously, it has been shown that CD68+ cells that express the G-CSF-
receptor mediate G-CSF-induced HSPC mobilization 32. We therefore propose that, in vivo, 
MSC-derived EV negatively affect this macrophage population, leading to downregulation of 
HSC retaining factors in the niche. This, in turn, induces a permissive state in the bone 
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marrow that allows for significantly enhanced HSPC mobilization when G-CSF is 
administered.  
In recent years, studies have indicated that MSC-derived EV are associated with a variety of 
hematopoietic disorders 33-35. MSC-derived EV are also thought to play a supporting role in 
tissue homeostasis and to influence responses to injury and infection 27,36. EV, secreted by 
murine- or human MSC, are able to inhibit radiation-induced apoptosis of the murine 
hematopoietic cell line FDC-P1 28. In addition to this, administration of MSC-derived EV 
resulted in long-term survival in lethally irradiated mice due to a direct radioprotective 
effect on HSC 37.  
In conclusion, both MSC and MSC-derived EV alter the stem cell niche and induce a 
permissive state in the BM. This state is characterized by macrophage depletion and 
downregulation of niche factors, thereby resulting in enhanced HSPC mobilization upon G-
CSF administration. Further studies will be required to identify the exact EV-component(s) 
that are responsible for the effects on the stem cell niche. Identification of these factor(s) 
may potentially lead to novel HSPC mobilization strategies. 
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Figure legends 
Figure 1. MSC administration increases HSPC cell cycle activity. Following 3 days of 
intravenous MSC or PBS administration, femurs were isolated and analyzed for (A) total 
WBC numbers and (B) the number of colony-forming cells (CFU-C); n=6-8 per group. (C-F) 
The absolute number of Lin-Sca-1+c-KitHICD34-CD135- (LSK), HSC, HPC and MPP per femur 
was determined by FACS analysis; n=6 per group. (G) Cell cycle activity of LSK cells was 
analyzed using a Ki67/DAPI staining. The frequencies of LSK cells in G0, G1 or S/G2/M was 
determined using flow cytometry. (H/I) Following 3 daily i.v. injections of MSC, mice 
received 5-FU at a dose of 150 mg/kg (day 0); WBC per ml of peripheral blood (H) and the 
absolute number of granulocytes per ml of peripheral blood (I) were determined at weekly 
intervals following 5-FU administration (n=5 per group). Data are depicted as mean ± SEM of 
2 separate experiments. *p<0.05, **p<0.01, ***p<0.001 all compared to PBS. 
 
Figure 2. MSC administration induces downregulation of niche factors in the bone marrow. 
(A-C) Osteomacs (n=12), (D-F) CD169+ macrophages (n=6) and (G) osteoclasts (n=10-13) 
were analyzed on day 4 after three consecutive days of PBS or MSC administration. Relative 
RNA expression for (H) Cxcl12, (I) Vcam and (J) Scf was determined in bone lining cells 
following PBS or MSC administration and depicted as relative expression compared to the 
household gene HPRT (n=11-15 from 5 separated experiments). K-M) Stromal cells 
downregulate (K) Cxcl12, (L) Vcam and (M) Scf upon cell-cell contact with RAW264.7 
macrophages. RAW264.7 cells are co-cultured with S17 or MS-5 stromal cells either in a 
transwell (TW) or in direct cell-cell contact (Well; n=4-11 from 2-5 separated experiments). 
Data are depicted as mean ± SEM. *p<0.05, **p<0.005, ***p<0.0005 all compared to PBS. 
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Figure 3. MSC enhance G-CSF-induced HSPC mobilization through a soluble factor. (A) MSC 
(M) were administered intravenously for 3 days at a dose of 200 x103 cells per day to 
recipients that were simultaneously mobilized with G-CSF (G; 10 μg per day intraperitoneally 
for 3 days) or PBS (P) as a control (n= 16-30 per group). (B) The absolute number of Lin-Sca-
1+c-KitHI in the peripheral blood was analyzed using flowcytometry (n=8-11 per group). (C) 
Equal numbers of peripheral blood cells obtained from G-CSF or MSC + G-CSF mobilized 
donors were transplanted into lethally irradiated recipients and donor chimerism for (C) 
total leukocytes and (D) granulocytes was assessed (n=10 per group). (E) IFN-γ -and TNF-α-
stimulated MSC enhance G-CSF mobilization at levels similar to unstimulated MSC. (F) MSC 
administration prior to G-CSF-induced mobilization significantly enhances HSPC 
mobilization. MSC were administered intravenously for 3 days at a dose of 200 x103 cells per 
day to recipients, followed by G-CSF administration on subsequent days (10 μg per day 
intraperitoneally for 2 or 3 days) or PBS as a control (n=3-6 from 2 independent 
experiments). (G-I) Relative RNA expression for (G) Cxcl12, (H) Vcam and (I) Scf was 
determined in bone lining cells following G-CSF or MSC + G-CSF administration and depicted 
as relative expression compared to the household gene HPRT (n=10-14 from 5 separated 
experiments). (J) MSC are trapped in the lung vasculature upon i.v. administration. Firefly-
luciferase-transduced MSC were administered for 3 days. At day 4, MSC were visualized by 
administration of luciferin followed by bioluminescence imaging. (K) Simultaneous 
administration of G-CSF and serum-free culture supernatant (S) enhances G-CSF-induced 
HSPC mobilization (n= 5 per group). Mean ± SEM are depicted. *p<0.05 **p<0.01 
***p<0.001. 
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Figure 4. MSC-derived extracellular vesicles enhance G-CSF-induced mobilization. (A) MSC 
(M) or EV that were derived from 2 x106-0.2 x106 MSC were administered intravenously for 
3 days to recipients that were simultaneously mobilized with G-CSF (G) or PBS (P) as a 
control. (n= 5-9 per group). (B) Cell cycle activity of LSK cells was analyzed using a Ki67/DAPI 
staining. The frequencies of LSK cells in G0, G1 or S/G2/M was determined and related to 
PBS controls; n=4-6 per group. (C-E) Relative RNA expression for (C) CXCL12, (D) VCAM and 
(E) SCF was determined in bone lining cells following MSC (M) or EV administration for 3 
days to recipients that were simultaneously mobilized with G-CSF (G) or PBS (P) as a control. 
Gene expression is depicted as relative expression compared to the household gene HPRT 
(n=3-6). Significance is indicated compared to P. # p=0.055) (F) PKH26-labeled EV are 
primarily taken up by monocytes. The percentage of CD45+ bone marrow cells, granulocytes 
(Gran), monocytes (Mon), B cells (B) and T cells (T) that have taken up EV are depicted 
within the total cell population. (G-H) Upon EV uptake, monocytes upregulate (G) F4/80, (H) 
CD68, (I) CD115 and (J) MERTK (data obtained from 1 experiment). EVneg cells are depicted 
as a dotted line, EVpos cells are depicted as filled histograms. Mean ± SEM are depicted. 
*p<0.05 **p<0.01 ***p<0.001. 
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Supplemental figure 1. MSC administration increases HSPC cell cycle activity. Following 3 
days of intravenous MSC, femurs were isolated. Using a Ki67/DAPI staining, cell cycle activity 
of (A) HSC and (B) HPC/MPP was analyzed and related to PBS controls. Data are depicted as 
mean ± SEM, n=7 per group **p<0.01 compared to PBS. 
 
Supplemental figure 2. Effect of MSC administration on the hematopoietic stem cell 
miroenvironment. Following 3 days of intravenous MSC or PBS administration (A) 
osteoprotegerin (OPG) levels were increased in bone marrow extracellular fluid upon MSC 
administration (n=3 per group). (B) OPG administration does not affect G-CSF-induced 
mobilization. OPG was administered at 10 μg or 1 μg per day for 3 days. At the same time 
points, PBS (P) or G-CSF (G) was administered; n=3-5 per group. (C) M-CSF (n=5-13) levels 
were determined in bone marrow extracellular fluid. Following 3 days of intravenous MSC 
or PBS administration B cells were significantly decreased in the (D) peripheral blood and (E) 
bone marrow (n=9-13). (F) This coincides with a decrease in Il-7 expression in bone-lining 
cells. p<0.05, **p<0.01, ***p<0.001 
 
Supplemental figure 3. (A) Splenocytes (S) were administered intravenously for 3 days at a 
dose of 200 x103 cells per day to recipients that were simultaneously mobilized with G-CSF 
(G; 10 μg per day intraperitoneally for 3 days) or PBS (P) as a control (n= 3 per group). Data 
are depicted as mean ± SEM. (B) Administration of MSC does not affect elastase levels in the 
bone marrow. Bone marrow extracellular extracts were obtained by flushing femurs with 
250 μl cold PBS. The cell suspension was centrifuged at 2,300 g for 5 minutes and the 
supernatant was stored at -20 C. Elastase activity was determined using the chromogenic 
substrate N-Succinyl-L-Ala-Ala-Ala-P-nitroanilide (Sigma, Zwijndrecht, The Netherlands). 
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Data are depicted as mean ± SEM (n=5-6) (C) Csf3R expression was assessed on peripheral 
blood cells (PB), bone marrow cells (BM) or MSC and depicted as relative expression 
compared to the household gene Abl (mean of triplicates are indicated).   
 
 
 
 
